Bitrobius Genetics is a biotechnology company focussed on realising the invention of a novel, DNA-based gene and cancer therapy platform technology called Gentrafix™. This promises to revolutionise disease treatment and prevention, by enabling most of the mutated copies of a gene in a target tissue or organ to be corrected using gene editing.

Bitrobius Genetics was founded in 2020 and is based in Alderley Park, Cheshire.